StreetInsider.com News Articles

AI/ML Innovations names new CFO, plans shares for debt settlement

Fri, 02 Oct 2026 07:52:14 -0400

AI/ML Innovations Inc. (CSE: AIML, OTCQB: AIMLF, FWB: 42FB) has appointed Lynn Chapman as Chief Financial Officer, effective October 1, 2026, replacing Terence Lee, according to a company statement.

Chapman holds a Chartered Professional Accountant designation from Alberta and has more than 15 years of financial and managerial experience. He has worked with publicly listed issuers on the Toronto Stock Exchange, TSX Venture Exchange, and Canadian Securities Exchange, as well as private companies across multiple industries and international jurisdictions. He began his career at KPMG LLP after earning a Bachelor of Business Administration from Mount Royal University.

Paul Duffy, Executive Chairman and

AI/ML Innovations names new CFO, plans shares for debt settlement

Fri, 02 Oct 2026 07:52:14 -0400

AI/ML Innovations Inc. (CSE: AIML, OTCQB: AIMLF, FWB: 42FB) has appointed Lynn Chapman as Chief Financial Officer, effective October 1, 2026, replacing Terence Lee, according to a company statement.

Paul Duffy, Executive Chairman and

AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement

Fri, 02 Oct 2026 07:50:00 -0400

TORONTO, ON / ACCESS Newswire / October 2, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company advancing artificial intelligence and neural-network-based technologies for digital health, is pleased to announce the appointment of Lynn Chapman, CPA, CA, as Chief Financial Officer of the Company, effective October 1, 2026.

Mr. Chapman is a Chartered Professional Accountant of Alberta with more than 15 years of financial and managerial experience. Throughout his career, he has provided business management, accounting, financial reporting, and advisory services to publicly listed issuers on the Toronto Stock Exchange,

AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement

Fri, 02 Oct 2026 07:50:00 -0400

AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement

Fri, 02 Oct 2026 07:50:00 -0400

AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement

Fri, 02 Oct 2026 07:50:00 -0400

AIML Subsidiary NeuralCloud Signs Binding Commercial Term Sheet with VetMed Consultants for MaxYield(TM) ECG Services

Thu, 01 Oct 2026 07:30:00 -0400

TORONTO, ON / ACCESS Newswire / October 1, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company advancing artificial intelligence and neural-network-based technologies for digital health, is pleased to announce that its wholly owned subsidiary, NeuralCloud Solutions Inc. ("NeuralCloud"), has signed a binding commercial term sheet and service level agreement, dated September 25, 2026, with VetMed Consultants, Inc. ("VetMed"), a Santa Fe, New Mexico-based preclinical cardiac safety consulting firm.

Under the agreement, the parties will follow a phased, gated pathway to evaluate whether NeuralCloud's MaxYield™ ECG signal-processing can support VetMed's

AIML Subsidiary NeuralCloud Signs Binding Commercial Term Sheet with VetMed Consultants for MaxYield(TM) ECG Services

Thu, 01 Oct 2026 07:30:00 -0400

Under the agreement, the parties will follow a phased, gated pathway to evaluate whether NeuralCloud's MaxYield™ ECG signal-processing can support VetMed's

AIML Subsidiary NeuralCloud Signs Binding Commercial Term Sheet with VetMed Consultants for MaxYield(TM) ECG Services

Thu, 01 Oct 2026 07:30:00 -0400

Under the agreement, the parties will follow a phased, gated pathway to evaluate whether NeuralCloud's MaxYield™ ECG signal-processing can support VetMed's

AIML Subsidiary NeuralCloud Signs Binding Commercial Term Sheet with VetMed Consultants for MaxYield(TM) ECG Services

Thu, 01 Oct 2026 07:30:00 -0400

Under the agreement, the parties will follow a phased, gated pathway to evaluate whether NeuralCloud's MaxYield™ ECG signal-processing can support VetMed's

NeuralCloud and RKS Medical to pilot CardioYield ECG software in Canada

Tue, 29 Sep 2026 07:30:18 -0400

AI/ML Innovations Inc. (CSE: AIML)(OTCQB: AIMLF)(FWB: 42FB) announced that its wholly owned subsidiary, NeuralCloud Solutions Inc., has entered into a partnership with Toronto-based RKS Medical Technologies to conduct pre-regulatory clearance pilot evaluations of its CardioYield™ software platform alongside RKS Medical's myPatch® Holter monitoring hardware.

Under the agreement, RKS Medical is expected to introduce NeuralCloud to clinics using or evaluating the myPatch®SL wireless Holter recorder. The pilots will assess how CardioYield™ performs as a software layer for ECG signal review, automated waveform analysis, report preparation, and workflow efficiency using recordings captured by myPatch® devices.

CardioYield™ is built on NeuralCloud's MaxYield™ signal-processing engine, which

NeuralCloud and RKS Medical to pilot CardioYield ECG software in Canada

Tue, 29 Sep 2026 07:30:18 -0400

CardioYield™ is built on NeuralCloud's MaxYield™ signal-processing engine, which

AIML Subsidiary NeuralCloud Enters Strategic Partnership with RKS Medical Technologies to Advance CardioYield(TM) Clinical Pilots

Tue, 29 Sep 2026 07:30:00 -0400

TORONTO, ON / ACCESS Newswire / September 29, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company advancing artificial intelligence and neural-network-based technologies for digital health, is pleased to announce that its wholly owned subsidiary, NeuralCloud Solutions Inc. ("NeuralCloud"), has entered into a strategic partnership with RKS Medical Technologies ("RKS Medical"), a Toronto-based medical technology company, to support clinical pilot deployments of NeuralCloud's CardioYield^™ software platform with RKS Medical's myPatch^® Holter monitoring technology.

RKS Medical, a leading M&A advisory firm in the diagnostic imaging sector also commercializes medical equipment and

AIML Subsidiary NeuralCloud Enters Strategic Partnership with RKS Medical Technologies to Advance CardioYield(TM) Clinical Pilots

Tue, 29 Sep 2026 07:30:00 -0400

RKS Medical, a leading M&A advisory firm in the diagnostic imaging sector also commercializes medical equipment and

AIML Subsidiary NeuralCloud Enters Strategic Partnership with RKS Medical Technologies to Advance CardioYield(TM) Clinical Pilots

Tue, 29 Sep 2026 07:30:00 -0400

RKS Medical, a leading M&A advisory firm in the diagnostic imaging sector also commercializes medical equipment and

AIML Subsidiary NeuralCloud Enters Strategic Partnership with RKS Medical Technologies to Advance CardioYield(TM) Clinical Pilots

Tue, 29 Sep 2026 07:30:00 -0400

RKS Medical, a leading M&A advisory firm in the diagnostic imaging sector also commercializes medical equipment and

AI/ML Innovations Launches Quantum Soma Initiative with Dynex Quantum Technologies for Contactless Quantum Biosensing Platform

Mon, 21 Sep 2026 07:30:00 -0400

TORONTO, ON / ACCESS Newswire / September 21, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company advancing artificial intelligence and neural-network-based technologies for digital health, is pleased to announce that it has launched Quantum Soma, a new AIML project focused on developing a contactless quantum biosensing platform that combines Dynex Quantum Technologies AG's ("Dynex") proprietary NV-diamond quantum sensing technology with AIML's MaxYield^™ signal-intelligence platform.

Effective September 21, 2026, AIML entered into a non-binding purchase order (the "Purchase Order") with Dynex for up to 2,000 units of Dynex's Single Zone

AI/ML Innovations Launches Quantum Soma Initiative with Dynex Quantum Technologies for Contactless Quantum Biosensing Platform

Mon, 21 Sep 2026 07:30:00 -0400

Effective September 21, 2026, AIML entered into a non-binding purchase order (the "Purchase Order") with Dynex for up to 2,000 units of Dynex's Single Zone

AI/ML Innovations Launches Quantum Soma Initiative with Dynex Quantum Technologies for Contactless Quantum Biosensing Platform

Mon, 21 Sep 2026 07:30:00 -0400

Effective September 21, 2026, AIML entered into a non-binding purchase order (the "Purchase Order") with Dynex for up to 2,000 units of Dynex's Single Zone

AI/ML Innovations Launches Quantum Soma Initiative with Dynex Quantum Technologies for Contactless Quantum Biosensing Platform

Mon, 21 Sep 2026 07:30:00 -0400

Effective September 21, 2026, AIML entered into a non-binding purchase order (the "Purchase Order") with Dynex for up to 2,000 units of Dynex's Single Zone

AI/ML Innovations closes final tranche of private placement at $0.05

Mon, 14 Sep 2026 17:00:13 -0400

AI/ML Innovations Inc. (CSE: AIML)(OTCQB: AIMLF)(FSE: 42FB) has closed the second and final tranche of its non-brokered private placement, issuing 7,300,000 units at $0.05 per unit to raise gross proceeds of $365,000, according to a company statement dated September 14, 2026.

Each unit consists of one common share and one common share purchase warrant. Each warrant is exercisable to acquire one additional common share at $0.15 for a period of 60 months from the date of issuance, subject to anti-dilution provisions.

In connection with the second tranche, the company issued 196,000 broker warrants to eligible finders, with each broker warrant carrying an

AI/ML Innovations closes final tranche of private placement at $0.05

Mon, 14 Sep 2026 17:00:13 -0400

In connection with the second tranche, the company issued 196,000 broker warrants to eligible finders, with each broker warrant carrying an

AI/ML Innovations Inc. Closes Final Tranche of Private Placement

Mon, 14 Sep 2026 17:00:00 -0400

TORONTO, ON / ACCESS Newswire / September 14, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement (the "Offering"). Pursuant to the second tranche of the Offering, the Company has issued an aggregate of 7,300,000 units ("Units") at a price of $0.05 per Unit to raise aggregate gross proceeds of $365,000. Each Unit is comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant

AI/ML Innovations Inc. Closes Final Tranche of Private Placement

Mon, 14 Sep 2026 17:00:00 -0400

AI/ML Innovations Inc. Closes Final Tranche of Private Placement

Mon, 14 Sep 2026 17:00:00 -0400